Safeguarding the Chain of Identity with Cell and Gene Therapies

As well as looking at the potential promised by cell and gene therapies, the industry meeting earlier this month evaluated the logistical challenges presented by these treatments. The niche supply chain hurdles are imposed by the unique logistics infrastructure required by cell and gene therapies (Patient > Manufacturer > Patient). Sascha Sonnenberg, President of Global CTD Sales & Operations at Marken presented a session on this topic at this years Cell and Gene Manufacturing Conferen...
To continue reading this story get free access